Tarlatamab improved survival in second-line treatment of small cell lung cancer
New approaches to small cell lung cancer require validation in larger trials. Concurrent thoracic radiotherapy with first-line chemoimmunotherapy increased toxicity without a survival benefit.
#tarlatamab #ivonescimab #irinotecan d8miq7k9f04rm.cloudfront.net